Skip to main content
Clinical Trials/NL-OMON40648
NL-OMON40648
Completed
N/A

A Prospective, Multi-Center Study of the IlluminOss® Photodynamic Bone Stabilization System for the Treatment of Impending and Actual Pathological Fractures in the Humerus from Metastatic Bone Disease - PBSS - Pathological Humerus Fractures

IlluminOss Medical In.0 sites4 target enrollmentTBD

Overview

Phase
N/A
Intervention
Not specified
Conditions
bone healing
Sponsor
IlluminOss Medical In.
Enrollment
4
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

Trial is onging in other countries

Registry
who.int
Start Date
TBD
End Date
March 14, 2016
Last Updated
2 years ago
Study Type
Interventional

Investigators

Sponsor
IlluminOss Medical In.

Eligibility Criteria

Inclusion Criteria

  • General inclusion criteria:
  • \- Skeletally mature adult males and females 18 years of age or older
  • \- Impending or actual pathological fracture of the humerus, secondary to metastatic bone disease
  • \- Females: neither pregnant nor intending to become pregnant during the course of the study
  • \- Able to understand and provide informed consent
  • \- Willing and able to comply with post\-operative treatment protocol and follow\-up visit schedule;Impending Fracture\-Specific Inclusion Criteria:
  • \- Documented presence of solitary metastatic lesion.
  • \- Mirels Criteria Score \>\= 8\.
  • \- Destruction of cortical bone at impending fracture site \> 50%.;Actual Fracture\-Specific Inclusion Criteria:
  • \- Radiograph\-confirmed diagnosis of acute, single isolated fracture of the humerus. AO classification 11A1, 11A2 and 11B1, 11B2 and 12A1,12A2 and 12B1, 12B2 and 13A1,13A2 and 13B1, 13B2\.

Exclusion Criteria

  • General Exclusion Criteria:
  • \- Primary tumor (osteogenic origin, etc.) at site
  • \- Impending fracture or actual fracture location other than humerus
  • \- Current concomitant traumatic fracture of any other location
  • \- Active or incompletely treated infections that could involve the device implant site
  • \- Distant foci of infection that may spread to the implant site
  • \- Allergy to implant materials or dental glue
  • \- Vascular insufficiency, muscular atrophy, or neuromuscular disease at implant site
  • \- Uncooperative patients, or patients who are incapable of following directions (for example, as a consequence of a neurological or psychiatric disorder);Impending Fracture\-Specific Exclusion Criteria:
  • \- Mirels Score \< 8

Outcomes

Primary Outcomes

Not specified

Similar Trials